Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness

Journal of Virology

Volumn 88, Issue 23, 2014, Pages 13769-13780

  Sui, Jianhua ^a,b,e   Deming, Meagan ^c   Rockx, Barry ^c,f   Liddington, Robert C ^d   Zhu, Quan Karen ^a,b   Baric, Ralph S ^c   Marasco, Wayne A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Stanford Burnham Medical Research   (United States)

^e NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES   (China)

^f University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; EPITOPE; MONOCLONAL ANTIBODY; VIRUS SPIKE PROTEIN; CORONAVIRUS SPIKE GLYCOPROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; VIRUS ANTIBODY; VIRUS RECEPTOR;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPIC PLASTICITY; PROTEIN DOMAIN; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR BINDING DOMAIN; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL PHENOMENA AND FUNCTIONS; VIROGENESIS; VIRUS ATTENUATION; VIRUS FITNESS; VIRUS MUTATION; VIRUS NEUTRALIZATION ESCAPE; VIRUS PATHOGENESIS; VIRUS VIRULENCE; ANIMAL; BAGG ALBINO MOUSE; HUMAN; IMMUNE EVASION; IMMUNOLOGY; METABOLISM; MUTATION; PATHOGENICITY; PHYSIOLOGY; SERODIAGNOSIS; VIRULENCE;

SARS CORONAVIRUS;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNE EVASION; MICE; MICE, INBRED BALB C; MUTATION; NEUTRALIZATION TESTS; PEPTIDYL-DIPEPTIDASE A; RECEPTORS, VIRUS; SARS VIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRULENCE;

EID: 84911383558     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02232-14     Document Type: Article

References (56)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367:1814-1820. http://dx.doi.org/10.1056 /NEJMoa1211721.
2. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota P, Fields B, DeRisi J, Yang JY, Cox N, Hughes JM, LeDuc JW, Bellini WJ, Anderson LJ. 2003. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348:1953-1966. http://dx.doi.org/10.1056 /NEJMoa030781.
3. Liang G, Chen Q, Xu J, Liu Y, Lim W, Peiris JS, Anderson LJ, Ruan L, Li H, Kan B, Di B, Cheng P, Chan KH, Erdman DD, Gu S, Yan X, Liang W, Zhou D, Haynes L, Duan S, Zhang X, Zheng H, Gao Y, Tong S, Li D, Fang L, Qin P, Xu W. 2004. Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerg. Infect. Dis. 10:1774-1781. http://dx.doi.org/10.3201/eid1010.040445.
4. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, Khattra J, Asano JK, Barber SA, Chan SY, Cloutier A, Coughlin SM, Freeman D, Girn N, Griffith OL, Leach SR, Mayo M, McDonald H, Montgomery SB, Pandoh PK, Petrescu AS, Robertson AG, Schein JE, Siddiqui A, Smailus DE, Stott JM, Yang GS, Plummer F, Andonov A, Artsob H, Bastien N, Bernard K, Booth TF, Bowness D, Czub M, Drebot M, Fernando L, Flick R, Garbutt M, Gray M, Grolla A, Jones S, Feldmann H, Meyers A, Kabani A, Li Y, Normand S, Stroher U, Tipples GA, Tyler S, Vogrig R, Ward D, Watson B, Brunham RC, Krajden M, Petric M, Skowronski DM, Upton C, Roper RL. 2003. The genome sequence of the SARS-associated coronavirus. Science 300:1399-1404. http://dx.doi.org/10.1126/science.1085953.
5. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TCT, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus ADME, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394-1399. http://dx.doi.org/10.1126 /science.1085952.
6. Anderson LJ, Tong S. 2010. Update on SARS research and other possibly zoonotic coronaviruses. Int. J. Antimicrob. Agents 36(Suppl 1):S21-S25. http://dx.doi.org/10.1016/j.ijantimicag.2010.06.016.
7. Hon CC, Lam TY, Shi ZL, Drummond AJ, Yip CW, Zeng F, Lam PY, Leung FC. 2008. Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus. J. Virol. 82:1819-1826. http://dx.doi .org/10.1128/JVI.01926-07.
8. Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, Wong SS, Leung SY, Chan KH, Yuen KY. 2005. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. U. S. A. 102:14040-14045. http://dx.doi.org/10.1073/pnas.0506735102.
9. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H, Zhang J, McEachern J, Field H, Daszak P, Eaton BT, Zhang S, Wang LF. 2005. Bats are natural reservoirs of SARS-like coronaviruses. Science 310:676-679. http://dx.doi.org/10.1126/science .1118391.
10. Poon LL, Chu DK, Chan KH, Wong OK, Ellis TM, Leung YH, Lau SK, Woo PC, Suen KY, Yuen KY, Guan Y, Peiris JS. 2005. Identification of a novel coronavirus in bats. J. Virol. 79:2001-2009. http://dx.doi.org/10 .1128/JVI.79.4.2001-2009.2005.
11. Vijaykrishna D, Smith GJ, Zhang JX, Peiris JS, Chen H, Guan Y. 2007. Evolutionary insights into the ecology of coronaviruses. J. Virol. 81:4012- 4020. http://dx.doi.org/10.1128/JVI.02605-06.
12. Ge XY, Li JL, Yang XL, Chmura AA, Zhu G, Epstein JH, Mazet JK, Hu B, Zhang W, Peng C, Zhang YJ, Luo CM, Tan B, Wang N, Zhu Y, Crameri G, Zhang SY, Wang LF, Daszak P, Shi ZL. 2013. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503:535-538. http://dx.doi.org/10.1038/nature12711.
13. Huynh J, Li S, Yount B, Smith A, Sturges L, Olsen JC, Nagel J, Johnson JB, Agnihothram S, Gates JE, Frieman MB, Baric RS, Donaldson EF. 2012. Evidence supporting a zoonotic origin of human coronavirus strain NL63. J. Virol. 86:12816-12825. http://dx.doi.org/10.1128/JVI.00906-12.
14. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. 2009. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7:226-236. http://dx.doi.org/10.1038/nrmicro2090.
15. Berry JD, Hay K, Rini JM, Yu M, Wang L, Plummer FA, Corbett CR, Andonov A. 2010. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. MAbs 2:53-66. http://dx.doi.org/10.4161/mabs.2.1.10788.
16. Coughlin M, Lou G, Martinez O, Masterman SK, Olsen OA, Moksa AA, Farzan M, Babcook JS, Prabhakar BS. 2007. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology 361:93-102. http://dx.doi.org/10.1016/j.virol.2006.09.029.
17. Coughlin MM, Babcook J, Prabhakar BS. 2009. Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms. Virology 394:39-46. http://dx.doi.org/10.1016/j.virol.2009.07.028.
18. Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, Jr, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan JL, Ambrosino DM. 2005. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J. Infect. Dis. 191:507-514. http://dx.doi.org/10.1086/427242.
19. Lai SC, Chong PC, Yeh CT, Liu LS, Jan JT, Chi HY, Liu HW, Chen A, Wang YC. 2005. Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV). J. Biomed. Sci. 12:711-727. http://dx.doi.org/10.1007/s11373-005-9004-3.
20. Lip KM, Shen S, Yang X, Keng CT, Zhang A, Oh HL, Li ZH, Hwang LA, Chou CF, Fielding BC, Tan TH, Mayrhofer J, Falkner FG, Fu J, Lim SG, Hong W, Tan YJ. 2006. Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus. J. Virol. 80:941-950. http://dx.doi.org/10.1128/JVI.80.2.941-950 .2006.
21. Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, Xiao X, Ji X, Dimitrov DS. 2006. Structure of severe acute respiratory syndrome coronavirus receptor- binding domain complexed with neutralizing antibody. J. Biol. Chem. 281:15829-15836. http://dx.doi.org/10.1074/jbc.M600697200.
22. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallarico AS, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, Marasco WA. 2004. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci. U. S. A. 101:2536-2541. http: //dx.doi.org/10.1073/pnas.0307140101.
23. ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, Haagmans BL, Kuiken T, de Kruif J, Preiser W, Spaan W, Gelderblom HR, Goudsmit J, Osterhaus AD. 2004. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363:2139- 2141. http://dx.doi.org/10.1016/S0140-6736(04)16506-9.
24. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A. 2004. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10:871-875. http://dx.doi.org/10.1038/nm1080.
25. Wang S, Chou TH, Sakhatskyy PV, Huang S, Lawrence JM, Cao H, Huang X, Lu S. 2005. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J. Virol. 79:1906-1910. http://dx.doi.org/10.1128/JVI.79.3.1906-1910.2005.
26. Zhang H, Wang G, Li J, Nie Y, Shi X, Lian G, Wang W, Yin X, Zhao Y, Qu X, Ding M, Deng H. 2004. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J. Virol. 78:6938-6945. http://dx.doi.org/10.1128/JVI.78.13.6938-6945.2004.
27. Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, Hensley LE, Prabakaran P, Rockx B, Sidorov IA, Corti D, Vogel L, Feng Y, Kim JO, Wang LF, Baric R, Lanzavecchia A, Curtis KM, Nabel GJ, Subbarao K, Jiang S, Dimitrov DS. 2007. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 104:12123-12128. http://dx.doi.org/10.1073/pnas.0701000104.
28. van den Brink EN, Ter Meulen J, Cox F, Jongeneelen MA, Thijsse A, Throsby M, Marissen WE, Rood PM, Bakker AB, Gelderblom HR, Martina BE, Osterhaus AD, Preiser W, Doerr HW, de Kruif J, Goudsmit J. 2005. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J. Virol. 79:1635-1644. http://dx .doi.org/10.1128/JVI.79.3.1635-1644.2005.
29. Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T, He Y. 2010. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol. J. 7:299. http://dx .doi.org/10.1186/1743-422X-7-299.
30. He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, Jiang S. 2005. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 334:74-82. http://dx.doi.org/10.1016/j.virol.2005.01 .034.
31. Lu L, Manopo I, Leung BP, Chng HH, Ling AE, Chee LL, Ooi EE, Chan SW, Kwang J. 2004. Immunological characterization of the spike protein of the severe acute respiratory syndrome coronavirus. J. Clin. Microbiol. 42:1570-1576. http://dx.doi.org/10.1128/JCM.42.4.1570-1576.2004.
32. Zakhartchouk AN, Sharon C, Satkunarajah M, Auperin T, Viswanathan S, Mutwiri G, Petric M, See RH, Brunham RC, Finlay BB, Cameron C, Kelvin DJ, Cochrane A, Rini JM, Babiuk LA. 2007. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine 25:136-143. http://dx.doi.org /10.1016/j.vaccine.2006.06.084.
33. Zhong X, Yang H, Guo ZF, Sin WY, Chen W, Xu J, Fu L, Wu J, Mak CK, Cheng CS, Yang Y, Cao S, Wong TY, Lai ST, Xie Y, Guo Z. 2005. B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein. J. Virol. 79:3401-3408. http://dx.doi.org/10.1128/JVI .79.6.3401-3408.2005.
34. Rockx B, Corti D, Donaldson E, Sheahan T, Stadler K, Lanzavecchia A, Baric R. 2008. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic SARS-CoV challenge. J. Virol. 82:3220-3235. http://dx.doi.org/10.1128 /JVI.02377-07.
35. Rockx B, Donaldson E, Frieman M, Sheahan T, Corti D, Lanzavecchia A, Baric RS. 2010. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J. Infect. Dis. 201:946-955. http://dx.doi.org/10.1086 /651022.
36. Hwang WC, Lin Y, Santelli E, Sui J, Jaroszewski L, Stec B, Farzan M, Marasco WA, Liddington RC. 2006. Structural basis of neutralization by a humananti-severe acute respiratory syndrome spike protein antibody, 80R. J. Biol. Chem. 281:34610-34616. http://dx.doi.org/10.1074/jbc.M603275200.
37. Sui J, Li W, Roberts A, Matthews LJ, Murakami A, Vogel L, Wong SK, Subbarao K, Farzan M, Marasco WA. 2005. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J. Virol. 79:5900 -5906. http://dx.doi.org/10.1128 /JVI.79.10.5900-5906.2005.
38. Sui J, Aird DR, Tamin A, Murakami A, Yan M, Yammanuru A, Jing H, Kan B, Liu X, Zhu Q, Yuan QA, Adams GP, Bellini WJ, Xu J, Anderson LJ, Marasco WA. 2008. Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog. 4:e1000197. http://dx.doi.org/10.1371/journal.ppat.1000197.
39. Sheahan T, Whitmore A, Long K, Ferris M, Rockx B, Funkhouser W, Donaldson E, Gralinski L, Collier M, Heise M, Davis N, Johnston R, Baric RS. 2011. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J. Virol. 85:217-230. http://dx.doi.org /10.1128/JVI.01805-10.
40. Yount B, Curtis KM, Fritz EA, Hensley LE, Jahrling PB, Prentice E, Denison MR, Geisbert TW, Baric RS. 2003. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. U. S. A. 100:12995-13000. http://dx.doi.org /10.1073/pnas.1735582100.
41. Rockx B, Corti D, Donaldson E, Sheahan T, Stadler K, Lanzavecchia A, Baric R. 2008. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J. Virol. 82:3220- 3235. http://dx.doi.org/10.1128/JVI.02377-07.
42. Rockx B, Sheahan T, Donaldson E, Harkema J, Sims A, Heise M, Pickles R, Cameron M, Kelvin D, Baric R. 2007. Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice. J. Virol. 81:7410-7423. http://dx.doi.org/10.1128/JVI.00505-07.
43. Harrison JL, Williams SC, Winter G, Nissim A. 1996. Screening of phage antibody libraries. Methods Enzymol. 267:83-109. http://dx.doi.org/10 .1016/S0076-6879(96)67007-4.
44. Reff ME,Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445.
45. Yang ZY, Huang Y, Ganesh L, Leung K, Kong WP, Schwartz O, Subbarao K, Nabel GJ. 2004. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J. Virol. 78:5642- 5650. http://dx.doi.org/10.1128/JVI.78.11.5642-5650.2004.
46. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450-454. http://dx.doi.org/10 .1038/nature02145.
47. Wong SK, Li W, Moore MJ, Choe H, Farzan M. 2004. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensinconverting enzyme 2. J. Biol. Chem. 279:3197-3201. http://dx.doi.org/10 .1074/jbc.C300520200.
48. Li F, Li W, Farzan M, Harrison SC. 2005. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309: 1864-1868. http://dx.doi.org/10.1126/science.1116480.
49. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16:265-273. http://dx.doi.org/10.1038/nsmb.1566.
50. Frieman M, Yount B, Agnihothram S, Page C, Donaldson E, Roberts A, Vogel L, Woodruff B, Scorpio D, Subbarao K, Baric RS. 2012. Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease. J. Virol. 86:884-897. http://dx.doi.org/10.1128/JVI.05957-11.
51. Li W, Greenough TC, Moore MJ, Vasilieva N, Somasundaran M, Sullivan JL, Farzan M, Choe H. 2004. Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2. J. Virol. 78:11429-11433. http://dx.doi .org/10.1128/JVI.78.20.11429-11433.2004.
52. Roberts A, Deming D, Paddock CD, Cheng A, Yount B, Vogel L, Herman BD, Sheahan T, Heise M, Genrich GL, Zaki SR, Baric R, Subbarao K. 2007. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 3:e5. http://dx.doi.org/10 .1371/journal.ppat.0030005.
53. Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M. 2005. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 24:1634-1643. http://dx.doi.org/10 .1038/sj.emboj.7600640.
54. Rani M, Bolles M, Donaldson EF, Van Blarcom T, Baric R, Iverson B, Georgiou G. 2012. Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus. J. Virol. 86:9113-9121. http://dx.doi.org/10.1128/JVI.00233-12.
55. Lai MM, Cavanagh D. 1997. The molecular biology of coronaviruses. Adv. Virus Res. 48:1-100.
56. Corti D, Lanzavecchia A. 2013. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 31:705-742. http://dx.doi.org/10.1146/annurev -immunol-032712-095916.